GLP-1 physiology informs the pharmacotherapy of obesity
Background: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D). These agents also inhibit food intake and reduce body weight,...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Knjiga |
| Izdano: |
Elsevier,
2022-03-01T00:00:00Z.
|
| Teme: | |
| Online dostop: | Connect to this object online. |
| Oznake: |
Označite
Brez oznak, prvi označite!
|
Internet
Connect to this object online.3rd Floor Main Library
| Signatura: |
A1234.567 |
|---|---|
| Kopija 1 | Prosto |